Dioscin inhibits ischemic stroke-induced inflammation through inhibition of the TLR4/MyD88/NF-κB signaling pathway in a rat model

SHILIN ZHU¹, SIYUAN TANG² and FENG SU³

¹Department of Neurology, The Second Affiliated Hospital, Hunan University of Chinese Medicine, Changsha, Hunan 410005; ²Xiang Ya Nursing School of Central South University, Changsha, Hunan 410013; ³Department of Emergency, Xiang Ya Hospital, Central South University, Changsha, Hunan 410008, P.R. China

Received August 28, 2016; Accepted May 23, 2017

DOI: 10.3892/mmr.2017.7900

Abstract. Diosgenin, as an essential natural steroidal saponin, can be extracted from numerous sources, primarily from fenugreek. It is an important raw material for the synthesis of steroid hormone drugs. It exhibits antitumor, anti-inflammatory, antioxidation and several other significant pharmacologic actions, and is of high pharmaceutical value. In the present study, the activities and underlying mechanisms of dioscin in the inhibition of ischemic stroke in rats were investigated. Inflammatory responses were analyzed using ELISA kits and caspase-3 and caspase-9 activity was analyzed using Caspase-3 and caspase-9 activity kits. Western blot analysis was used to measure Toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), nuclear factor-kappa B (NF-κB), transforming growth factor-beta (TGF-β), high-mobility group protein 1 (HMGB-1), interleukin-1 receptor-associated kinase 1 (IRAK1), and tumor necrosis factor receptor-associated factor 6 (TRAF6) protein expression. Dioscin inhibited infarct volume and neurological scores in the ischemic stroke rat model. The results demonstrated that dioscin reduced inflammatory responses, and suppressed the expression of TLR4, MyD88, NF-κB, TGF-β, HMGB-1, IRAK1, and TRAF6 in the rat ischemic stroke model. Taken together, these findings suggested that dioscin inhibited ischemic stroke-induced inflammation through inhibition of the TLR4/MyD88/NF-κB-mediated inflammation the rat model, which provided novel insights into the mechanisms underlying the effect of dioscin as an anti-inflammatory candidate for the treatment of ischemic stroke in the future.

Introduction

Ischemic stroke is the most common type of cerebrovascular disease, accounting for 85% of all cerebrovascular diseases. It is ranked third among life-threatening diseases and is the most disabling disease worldwide (1). It severely affects human health and, within 3 months following a stroke, ~15-30% of survivors suffer from permanent disability, including paralysis, memory disorders, thought disorders, linguistic problems and akinesia (2). Of these individuals, ~20% require care as they cannot perform self-care. In western countries, >70% of the population >65 years old experience a stroke (3), and the number of patients continues to increase (3). Although the pathology and physiology of ischemic stroke involve different mechanisms, increasing evidence has indicated that ischemic damage and inflammation lead to disease progression (4). Cerebral ischemia induces pathological pathways in an ischemia cascade reaction and causes irreversible damage of ischemic core neurons (5).

At present, substantial evidence has shown that the essential mechanism of cerebral ischemic injury involves oxidative stress and inflammatory reaction (6). The use of psychotherapeutic drugs for anti-inflammatory treatment has provided scope clinically, including for the treatment of tumors (7), and it has shown preliminary treatment effects. Consequently, theoretical and clinical investigations aimed at enhancing the inflammatory mechanism following cerebral ischemia is likely to generate novel opportunities for the treatment of cerebral infarction (6,8).

Toll-like receptor 4 (TLR4) is a transmembrane receptor protein composed of an extracellular region, transmembrane region and intracellular region (9). Through recognition of high-mobility group protein 1 (HMGB1), heat shock protein, fibrous protein, necrocytosis components and other molecules released at sites of histocyte damage, TLR4 further activates the signal transduction pathway in the cell to enhance the synthesis and release of cytokines, promoting the maturation and differentiation of immune cells and regulating the immune response (9). In peripheral regions, TLR4 is predominantly distributed on
lymphocytes, macrophages, dendritic cells and other innate immunocytes, and is involved in immune responses to bacteria and other exogenous pathogens. In the central nervous system, TLR4 distributes extensively on astrocytes, microglial cells, vascular endothelium and smooth muscle cytomebrobes, and is involved in the pathogenic process of Parkinson's disease, Alzheimer’s disease and other neurodegenerative diseases (10). The activated TLR4 can activate nuclear factor-κB (NF-κB) in a resting state, which translocates to the cell nucleus to initiate the gene expression of TNF-4 interleukin (IL)-1, cyclooxygenase-2 (COX-2) and other adhesion molecules through combining with myeloid differentiation antigen 88 (MyD88), leading to inflammatory reactions (11).

Diosgenin, generally known as saponin, is a natural and synthetic steroid sapogenin belonging to a screw sterase alcohol glucoside (Fig. 1) (12). The relative molecular mass is 414.63, and is present extensively in leguminosae and dioscoraceous plants. Diosgenin is found in the seeds of fenugreek Trigonella foenum-graecum L. (13). It can also be extracted from the tuber of Dioscorea zingiberensis C. H. Wright, D. nipponica Makino, D. panthaica Prain et Burkill and D. nipponica Makino ssp. Rosthornii (Prain et Burkill) C. T. Ting through methods, including hydrolyzation, fermentation and extraction (14). Diosgenin, as an essential raw material for the synthesis of steroid hormone drugs and steroidal contraceptives, is used to produce pregnenolone, progesterone and cortisone (15). Previous in-depth investigations of the pharmacologic actions of diosgenin have been performed. Diosgenin has antitumor effects in addition to blood lipid-regulating, anti-platelet aggregating and bifilaction-promoting effects (14). It is an essential drug for the treatment of cardiovascular disease, encephalitis, dermatosis and tumors (15,16). Therefore, the aim of the present study was to investigate the neuroprotective effect of dioscin on inhibiting the effects of ischemic stroke and its possible mechanisms.

Materials and methods

Animals. Adult male Sprague-Dawley rats (8-10 weeks old, 200-230 g) were purchased from the Hunan Experimental Animal Centre of Hunan University of Chinese Medicine (Hunan, China) and fed a commercially available liquid diet. The rats were housed in separate cages in a room with controlled temperature (22-24°C), 12 h light:dark cycle (light between 8:00 and 20:00) and humidity (50-55%). The protocols used in the present study followed the National Institutes of Health guidelines for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD, USA), were approved by the institutional animal ethics committee of Hunan University of Chinese Medicine of Medicine. Following 1 week of acclimatization, the rats were randomly divided into three groups (n=8 per group) as follows: Sham group, stroke model group, and dioscin treatment group. In the dioscin treatment group, the rats were intragastrically treated with 80 mg/kg/day of dioscin for 4 weeks.

Middle cerebral artery occlusion (MCAO). All rats were anesthetized with 2.5% isoflurane (Forane; Abbot Japan, Tokyo, Japan) and were maintained at 37±1°C during the experiment. The right common carotid artery was exposed using a midline neck incision, and 4-cm poly-L-lysine-coated nylon thread (3-0) was inserted into the internal carotid artery through the right common carotid artery and gently advanced until resistance was detected in the blood flow trace. MCAO was maintained for 2 h, following which the thread was gently removed to restore blood flow. The wounds were sterilized and sutured, and the rats were allowed to recover from anesthesia.

Neurological assessment. The modified neurological severity score was used to assess neurologic severity scores. The neurologic function was graded with scores between 0 and 5 (0, no neurologic deficit; 5, maximal deficit). A score of 1 indicated that the rats were unable perform the test or the tested reflex, and a higher score indicated more severe injury.

Following anesthesia with 2.5% isoflurane, the rats were sacrificed and their brains were removed, cleaned and solidified using pre-cooled normal saline (4°C) for 5 min. The prepared slices (5 µM) were stained with 2% 2,3,5-triphenyltetrazolium chloride (Sigma; Merck Millipore; Darmstadt, Germany) and fixed in 10% buffered formalin solution. Images were captured using light microscopy (Nikon Eclipse TE2000-U; Nikon, Tokyo, Japan).

Determination of biological indicators. Following anesthesia with 2.5% isoflurane, the rats were sacrificed, following which their brains were removed and cleaned, and the hippocampus was separated. Total cellular protein was lysed from the hippocampal tissue using radioimmunoprecipitation lysis buffer (Beyotime Institute of Biotechnology, Jiangsu, China) and the protein content was determined using a BCA protein assay kit (Beyotime Institute of Biotechnology). The proteins (5 µM) were incubated with the caspase-3 and caspase-9 activity kits (Ac-DEVD-pNA and Ac-LEHD-pNA) for 2 h at 37°C. The color intensity was measured at 405 nm. The proteins (10 µg) were subjected to 8-12% SDS-PAGE and then transferred

![Figure 1. Structural formula of dioscin.](image-url)
onto a nitrocellulose membrane (EMD Millipore, Billerica, MA, USA). The membrane was blocked by incubation with 5% (w/v) nonfat milk in Tris-buffered saline with Tween-20 (Sigma-Aldrich; Merck Millipore). The membrane was then incubated with anti-IRAK1 (cat. no. sc-7883, 1:500, Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-TRAF6 (cat. no. sc-7221, 1:500, Santa Cruz Biotechnology, Inc.), anti-HMGB-1 (cat. no. sc-135809, 1:500, Santa Cruz Biotechnology, Inc.), anti-TLR4 (cat. no. sc-293072, 1:500, Santa Cruz Biotechnology, Inc.), anti-MyD88 (cat. no. sc-11356, 1:500, Santa Cruz Biotechnology, Inc.), anti-NF-kB (cat. no. sc-7178, 1:500, Santa Cruz Biotechnology, Inc.) and anti-GAPDH (cat. no. AG019, 1:2,000, Beyotime Institute of Biotechnology) antibodies overnight at 4°C. The blots were then incubated with anti-rabbit horseradish peroxidase-conjugated antibodies (cat. no. A0208, 1:5,000, Beyotime Institute of Biotechnology) for 1 h at room temperature. The protein blank was detected using enhanced chemiluminescence (Beyotime Institute of Biotechnology) method and images were captured using the Image Lab (version 3.0; Bio-Rad Laboratories, Inc., Hercules, CA, USA).

**Statistical analysis.** All data are expressed as the mean ± standard deviation and analysed using SPSS software (version 19.0; IBM Corp., Armonk, NY, USA). One-way analysis of variance was performed to compare the differences between two groups, followed by Duncan's test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Effect of dioscin on infarct volume and neurological scores in rats with ischemic stroke.** In order to confirm the effect of dioscin on ischemic stroke, the infarct volume and neurological scores were determined. As shown in Fig. 2A, there were significant increases in infarct volume and neurological scores in the ischemic stroke group, compared with the sham control group. By contrast, treatment with dioscin significantly reduced the ischemic stroke-induced infarct volume and neurological scores in the ischemic stroke model (Fig. 2B).

**Effect of dioscin on inflammatory responses in the rat ischemic stroke model.** To further confirm the inhibitory effect of dioscin on the ischemic stroke rats, the activities of IL-1β, IL-6 and TNF-α were measured using ELISA kits. As shown in Fig. 3A-D, the results indicated that there were decreases in the activities of IL-1β, IL-6 and TNF-α and a decrease in the activity of IL-10 in the rats of the ischemic stroke model, compared with those in the control group. In addition, dioscin treatment significantly inhibited the activities of IL-1, IL-6 and TNF-α in the rats of the ischemic stroke model (Fig. 3).

**Effect of dioscin on activities of caspase-3/9 in the rat ischemic stroke model.** To further confirm the involvement of caspase activation in the effect of dioscin on apoptosis in rats with ischemic stroke, caspase-3 and caspase-9 kits were used to measure these indices. The activities of caspase-3 and caspase-9 in the rats of the ischemic stroke model were increased, compared with those in the sham control group (Fig. 4A and B). Treatment with dioscin significantly inhibited the activities of caspase-3 and caspase-9 in the rat ischemic stroke model (Fig. 4A and B).

**Effect of dioscin on the activity of TGF-β1 in the rat ischemic stroke model.** To determine whether the effect of dioscin affects the activity of TGF-α in the rats of the ischemic stroke model, the activities of TGF-α were measured using ELISA kits. Compared with that in the sham control group, the activity of TGF-α in the ischemic stroke model was enhanced (Fig. 5). Treatment with dioscin significantly suppressed the activity of TGF-β1 in the ischemic stroke model (Fig. 5).

**Effect of dioscin on the protein expression levels of IRAK1 and TRAF6 in the rat ischemic stroke model.** The present study examined the protein expression levels of IRAK1 and TRAF6 in the rats of the ischemic stroke model treated with dioscin. As shown in Fig. 6A-C, the protein expression levels of IRAK1 and TRAF6 in the ischemic stroke group were higher, compared with those of the sham control group. Dioscin markedly reduced the protein expression levels of IRAK1 and TRAF6 in the ischemic stroke model (Fig. 6A-C).

**Effect of dioscin on the protein expression levels of HMGB-1 in the rat ischemic stroke model.** The present study assessed whether dioscin affected the protein expression levels of HMGB-1 in the rats ischemic stroke model. As shown in Fig. 7A and B, the protein expression of HMGB-1 in the ischemic stroke group was increased, compared with that in the sham group. The induced protein expression of HMGB-1
in the ischemic stroke group was significantly suppressed by dioscin (Fig. 7A and B).

**Effect of dioscin on the protein expression levels of TLR4 in the rat ischemic stroke model.** In order to examine the effects of the administration of dioscin on stroke, western blot analysis was performed to measure the protein expression levels of TLR4 in the ischemic stroke group. As shown in Fig. 8A and B, the protein expression level of TLR4 in the ischemic stroke group was markedly increased, compared with that on the sham control group. However, treatment with dioscin significantly suppressed the protein expression of TLR4 in the ischemic stroke group (Fig. 8A and B).

**Effect of dioscin on the protein expression of MyD88 in the rat ischemic stroke model.** The present study also examined the protein expression levels of MyD88 in rats with ischemic stroke treated with dioscin using western blotting analysis. As shown in Fig. 9A and B, the protein expression of MyD88 in ischemic stroke group was higher, compared with that in the sham control group. Dioscin treatment significantly suppressed the protein expression of MyD88 in the ischemic stroke group (Fig. 9A and B).

**Effect of dioscin on the protein expression of NF-κB in the rat ischemic stroke model.** To investigate the possible role
of NF-κB invpathways in the effects of dioscin on ischemic stroke, the protein expression levels of NF-κB were examined using western blot analysis. The results of the western blot analysis showed that the protein expression of NF-κB was significantly increased in the ischemic stroke group, compared with that in the sham control group. By contrast, dioscin treatment significantly suppressed the protein expression of NF-κB in the ischemic stroke group (Fig. 10A and B).

Discussion

Acute cerebral infarction is also known as apoplexy or cerebral apoplexy. It is one of the most complicated nervous system diseases with the highest level of damage. It has been ranked as the third leading cause of mortality and the leading contributor to disability (17). Following thrombosis, sudden interruption or cerebral blood flow or emboli, patients suffer from symptoms, including paralysis, language damage and eyesight loss (18). In addition, <15% of cases are caused by hemorrhagic stroke or cardiac arrest. According to statistical data of the United States in 2014, the average rate of stroke occurrence was once every 40 sec, with associated mortality every 4 min (4). The estimated mortality rate has reached 41.6% and, with an increasingly aging population the rates are likely to increase correspondingly. The data obtained in the present study suggested that treatment with dioscin significantly reduced ischemic stroke-induced infarct volume and neurological scores in the ischemic stroke model.
stress and autophagy. On reviewing the time-scale of cerebral ischemia/reperfusion injury, inflammatory reactions become apparent up to 2 h following ischemia, and further aggravate cerebral tissue damage (19). As a result of hematoencephalic barrier effects, the inflammatory reactions following ischemia are divided into central sleep apnea and peripheral (20).

Initially, at the early stage of cerebral ischemia/reperfusion injury, free radicals, cell toxicity and other substances released by the ‘infarction core’ activate the microglia inherent inflammatory cells in the central nervous system, and induce microglial cells to release TNF-α (21). Tao et al confirmed that dioscin ameliorates inflammation through TLR4 signaling via the inhibition of HMGB-1 in an in vitro cerebral ischemia/reperfusion injury model (22).

These results showed that Dioscin treatment significantly inhibited the activities of IL-1β, IL-6, TNF-α, caspase-3 and caspase-9 in the ischemic stroke rats, which showed that the dioscin-induced inhibition of ischemic stroke was dependent on the inflammation and anti-apoptotic effects.

TLRs are one of the most important pattern recognition receptor families, and have key effects on the induction of inflammatory reactions and generation of the inflammatory medium process (23). All TLRs are enriched in the extracellular region of leucine-rich repeat sequences, and is necessary for recognizing pathogen-associated molecular patterns (PAMPs) (24). In addition, the intracellular Tol I-interleukin-1 receptor structural domain is required for initiating intracellular signal transduction. The aforementioned structure can recognize conserved molecular structures and microorganism products, including the endogenous molecular patterns of PAMPs and tissue damage (25). A previous study have shown that the expression of TLR4 is upregulated in an ischemic stroke model (25), expressed predominantly on microglial cells and neurons. In addition, in a mouse model with TLR4 defect, nerve function loss and brain damage were less marked, compared with those in wild-type mice (26). TLR activation leads to the translocation of NF-κB. It is a key regulatory factor mediating the expression of inflammatory mediators and the inflammatory reaction. Inhibiting its activity reduces brain damage (27). The results of the present study showed that dioscin significantly suppressed the activity of TGF-β1, reduced the protein expression levels of IRAK1 and TRAF6, and suppressed the protein expression levels of HMGB-1 and TLR4 in the rats of the ischemic stroke model. Liu et al showed that dioscin alleviates alcoholic liver fibrosis through the TLR4/MyD88/NF-κB signaling pathway (13). Therefore, the effect of dioscin on ischemic stroke may be associated with the TLR4 pathway.

The TLR4/NF-κB signal transduction pathway activates downstream inflammatory cytokines, including TNF-α, IL-6, IL-10, C-X-C motif chemokine ligand-10, interferon-F and chemokines, and upregulates the expression of cell adhesion molecules. In addition, the expression of matrix metalloproteinase (MMP)-9 in ischemic brain tissue increases with pro-inflammatory effects (11,28). The cytokines generated following ischemia can induce the generation of MMP, which causes an increase in vasopermeability and blood-brain barrier (BBB) damage. This further promotes microvascular basement membrane protein hydrolysis and vasogenic cerebral edema generation, and leads to increased cerebral ischemia, BBB destruction, encephaledeadema, neuronal cell death, and

Figure 9. Effect of dioscin on protein expression levels of MyD88 in ischemic stroke rats. (A) Effect of dioscin on protein expression of MyD88 was determined using western blot analysis. (B) Statistical analysis of protein expression levels of MyD88 in ischemic stroke rats. Control, control group; Stroke, ischemic stroke model group; Dioscin, dioscin treatment group. ##P<0.01, vs. control group; ###P<0.01, vs. ischemic stroke model group. MyD88, myeloid differentiation factor 88.

Figure 10. Effect of dioscin on protein expression levels of NF-κB in ischemic stroke rats. (A) Effects of dioscin on protein expression of NF-κB was determined using western blot analysis. (B) Statistical analysis of protein expression levels of NF-κB in ischemic stroke rats. Control, control group; Stroke, ischemic stroke model group; Dioscin, dioscin treatment group. ##P<0.01, vs. control group; ###P<0.01, vs. ischemic stroke model group. NF-κB, nuclear factor-kappa B.
Further aggravation of brain damage (10). Qi et al found that Dioscin alleviates LPSt-induced inflammatory kidney injury via the TLR4/MyD88 signaling pathway (12). The results of the present study showed that Dioscin treatment significantly also suppressed the protein expression levels of MyD88 and NF-κB in the rats of the ischemic stroke model, and downregulated the TLR4/MyD88/NF-κB pathway.

In conclusion, based on the observations of the present study, Dioscin significantly reduced ischemic stroke-induced infarct volume and neurological scores, and inhibited ischemic stroke-induced inflammation and expression levels of TGF-β-1. If administered before ischemia, Dioscin alleviates mTBI through downregulating TLR4/MyD88/MyD88 signaling. Dioscin may have anti-inflammatory, anti-apoptotic and other effects, which require confirmation in the future, in addition to clinical application to provide further data to support the findings obtained in the present study.

References